Vaxcyte (PCVX) Stock Soars As VAX-31 Data Smash Expectations
Vaxcyte Inc. (PCVX) stock rose 8.72% on October 9, 2026, following positive data from its VAX-31 vaccine trial, which met all primary endpoints. The stock saw a significant surge after the OPUS-1 trial results, with analysts setting price targets up to $163. Vaxcyte reported strong financials but remains pre-revenue with ongoing R&D expenses.
How this was made
The 30-second read
Why it matters
Analyst upgrades and target hikes reflect de‑risking; momentum may sustain short‑term but long‑term upside depends on BLA filing and financing.
Market read
The trial data creates a catalyst for PCVX and may lift peer biotech stocks.
What to watch
Dilution from upcoming $1B raise and cash burn could limit upside if momentum fades.
Background
Vaxcyte (PCVX) announced positive Phase 3 data for its VAX-31 pneumococcal vaccine, triggering a sharp stock move.
Ticker impact
Positive Phase 3 OPUS-1 trial data for VAX-31 vaccine drove an 8%+ intraday surge and analyst target upgrades.
upward bias as momentum continues, with potential pull‑back near $70 support.
Analyst upgrades and $146‑$163 target range suggest further upside; price may test $120‑$150 zone if rally sustains.
Market effects
Biotech sector may see broader rally on positive late‑stage trial news.
U.S. biotech stocks gain as investors reprice clinical risk.
Positive vaccine data could influence global pneumococcal market outlook.
Counterpoint
If the rally is driven by short‑cover, a pull‑back to $60‑$65 is possible.
Key entities
- companyVaxcyte Inc.
Clinical‑stage biotech developing VAX-31 vaccine.
- analystJefferies
Raised price target to $146 on trial success.
